BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 9882513)

  • 1. Regulatory role of mevalonate and N-linked glycosylation in proliferation and expression of the EWS/FLI-1 fusion protein in Ewing's sarcoma cells.
    Wang M; Xie Y; Girnita L; Nilsson G; Dricu A; Wejde J; Larsson O
    Exp Cell Res; 1999 Jan; 246(1):38-46. PubMed ID: 9882513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A link between basic fibroblast growth factor (bFGF) and EWS/FLI-1 in Ewing's sarcoma cells.
    Girnita L; Girnita A; Wang M; Meis-Kindblom JM; Kindblom LG; Larsson O
    Oncogene; 2000 Aug; 19(37):4298-301. PubMed ID: 10980604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of N-linked glycosylation down-regulates insulin-like growth factor-1 receptor at the cell surface and kills Ewing's sarcoma cells: therapeutic implications.
    Girnita L; Wang M; Xie Y; Nilsson G; Dricu A; Wejde J; Larsson O
    Anticancer Drug Des; 2000 Feb; 15(1):67-72. PubMed ID: 10888037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preferential down-regulation of phospholipase C-beta in Ewing's sarcoma cells transfected with antisense EWS-Fli-1.
    Dohjima T; Ohno T; Banno Y; Nozawa Y; Wen-yi Y; Shimizu K
    Br J Cancer; 2000 Jan; 82(1):16-9. PubMed ID: 10638960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation.
    Mateo-Lozano S; Tirado OM; Notario V
    Oncogene; 2003 Dec; 22(58):9282-7. PubMed ID: 14681687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting of EWS/FLI-1 by RNA interference attenuates the tumor phenotype of Ewing's sarcoma cells in vitro.
    Chansky HA; Barahmand-Pour F; Mei Q; Kahn-Farooqi W; Zielinska-Kwiatkowska A; Blackburn M; Chansky K; Conrad EU; Bruckner JD; Greenlee TK; Yang L
    J Orthop Res; 2004 Jul; 22(4):910-7. PubMed ID: 15183454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined transcriptional and translational targeting of EWS/FLI-1 in Ewing's sarcoma.
    Mateo-Lozano S; Gokhale PC; Soldatenkov VA; Dritschilo A; Tirado OM; Notario V
    Clin Cancer Res; 2006 Nov; 12(22):6781-90. PubMed ID: 17121899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GSTM4 is a microsatellite-containing EWS/FLI target involved in Ewing's sarcoma oncogenesis and therapeutic resistance.
    Luo W; Gangwal K; Sankar S; Boucher KM; Thomas D; Lessnick SL
    Oncogene; 2009 Nov; 28(46):4126-32. PubMed ID: 19718047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stimulatory effect of PDGF on HMG-CoA reductase activity and N-linked glycosylation contributes to increased expression of IGF-1 receptors in human fibroblasts.
    Carlberg M; Larsson O
    Exp Cell Res; 1996 Feb; 223(1):142-8. PubMed ID: 8635486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro.
    Kovar H; Aryee DN; Jug G; Henöckl C; Schemper M; Delattre O; Thomas G; Gadner H
    Cell Growth Differ; 1996 Apr; 7(4):429-37. PubMed ID: 9052984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of apoptosis by normal and aberrant Fli-1 and erg proteins involved in human solid tumors and leukemias.
    Yi H; Fujimura Y; Ouchida M; Prasad DD; Rao VN; Reddy ES
    Oncogene; 1997 Mar; 14(11):1259-68. PubMed ID: 9178886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells Results in EWS/FLI-1-dependent, ewing sarcoma-like tumors.
    Castillero-Trejo Y; Eliazer S; Xiang L; Richardson JA; Ilaria RL
    Cancer Res; 2005 Oct; 65(19):8698-705. PubMed ID: 16204038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface. Evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme a reductase and cell growth.
    Carlberg M; Dricu A; Blegen H; Wang M; Hjertman M; Zickert P; Höög A; Larsson O
    J Biol Chem; 1996 Jul; 271(29):17453-62. PubMed ID: 8663239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential regulation of the response to DNA damage in Ewing's sarcoma cells by ETS1 and EWS/FLI-1.
    Soldatenkov VA; Trofimova IN; Rouzaut A; McDermott F; Dritschilo A; Notario V
    Oncogene; 2002 Apr; 21(18):2890-5. PubMed ID: 11973649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells.
    Tanaka K; Iwakuma T; Harimaya K; Sato H; Iwamoto Y
    J Clin Invest; 1997 Jan; 99(2):239-47. PubMed ID: 9005992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The sensitivity of the Ewing's sarcoma family of tumours to fenretinide-induced cell death is increased by EWS-Fli1-dependent modulation of p38(MAPK) activity.
    Myatt SS; Burchill SA
    Oncogene; 2008 Feb; 27(7):985-96. PubMed ID: 17700534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of tenascin-C by tumor-specific EWS-ETS fusion genes.
    Watanabe G; Nishimori H; Irifune H; Sasaki Y; Ishida S; Zembutsu H; Tanaka T; Kawaguchi S; Wada T; Hata J; Kusakabe M; Yoshida K; Nakamura Y; Tokino T
    Genes Chromosomes Cancer; 2003 Mar; 36(3):224-32. PubMed ID: 12557222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein.
    Hahm KB; Cho K; Lee C; Im YH; Chang J; Choi SG; Sorensen PH; Thiele CJ; Kim SJ
    Nat Genet; 1999 Oct; 23(2):222-7. PubMed ID: 10508522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma.
    Lin PP; Brody RI; Hamelin AC; Bradner JE; Healey JH; Ladanyi M
    Cancer Res; 1999 Apr; 59(7):1428-32. PubMed ID: 10197607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells.
    Riggi N; Cironi L; Provero P; Suvà ML; Kaloulis K; Garcia-Echeverria C; Hoffmann F; Trumpp A; Stamenkovic I
    Cancer Res; 2005 Dec; 65(24):11459-68. PubMed ID: 16357154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.